ArticleHypertension (Dallas, Tex. : 1979)2020
Cost-Effectiveness of Drug Treatment for Chinese Patients With Stage I Hypertension According to the 2017 Hypertension Clinical Practice Guidelines.
Article in Hypertension (Dallas, Tex. : 1979), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Effects of different exercise modalities on blood pressure and endothelial function in prehypertension individuals: a systematic review and network meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Short-term efficacy of non-pharmacological interventions for global population with elevated blood pressure: A network meta-analysis.Frontiers in public health · 2022Pooled it
- Blood pressure categories defined by the 2017 ACC/AHA guideline and all-cause mortality: a national cohort study in China and meta-analysis.Journal of human hypertension · 2022Pooled it
- Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials.Frontiers in public health · 2022Pooled it
- Effect of Tai Chi vs Aerobic Exercise on Blood Pressure in Patients With Prehypertension: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Lifetime health benefits, costs, and cost-effectiveness of salt substitution for stroke survivors in China: a microsimulation modeling study.The Lancet regional health. Western Pacific · 2026Article
- Prevention of dementia using mobile phone applications (PRODEMOS) - a health-economic cost-utility analysis in people aged 55-75 years with low socio-economic status.The journal of prevention of Alzheimer's disease · 2026Article
- Physical Activity Recommendations Tailored by a Predictive Model for Adults With High Blood Pressure: Observational Study.Journal of medical Internet research · 2026Observational
- Cost-effectiveness of cardiovascular risk assessment and management among adults with hypertension in China: A modelling study.American journal of preventive cardiology · 2025Article
- Cost-effectiveness analysis of a nonphysician-led, community-based blood pressure intervention in rural China based on CRHCP research.International journal of technology assessment in health care · 2024Article
- Cost-Effectiveness of Salt Substitution and Antihypertensive Drug Treatment in Chinese Prehypertensive Adults.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Cost-Effectiveness of a Workplace-Based Hypertension Management Program in Real-World Practice in the Kailuan Study.Journal of the American Heart Association · 2024Article
- Cost-effectiveness of treatment in adults with blood pressure of 130-139/80-89 mmHg and high cardiovascular risk in China: a modelling study.The Lancet regional health. Western Pacific · 2024Article
- Cost-effectiveness of drug treatment for young and middle-aged stage 1 hypertensive patients with high risk.Journal of global health · 2023Article
- Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China.BMC public health · 2023Article
- The blood pressure control and arteriosclerotic cardiovascular risk among Chinese community hypertensive patients.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
Systolic/diastolic blood pressure of 130 to 139/80 to 89 mm Hg has been defined as stage I hypertension by the 2017 Hypertension Clinical Practice Guidelines. Drug treatment is recommended for stage I hypertensive patients aged ≥65 years without cardiovascular disease in the 2017 Hypertension Clinical Practice Guidelines but not in the 2018 Chinese guidelines. However, the cost-effectiveness of drug treatment among this subgroup of Chinese patients is unclear. This study developed a microsimulation model to compare costs and effectiveness of drug treatment and nondrug treatment for the subgroup of stage I hypertensive patients over a lifetime horizon from a government affordability perspective. Event rates of mortality and cardiovascular complications were estimated from 3 cohorts in the Chinese population. Costs and health utilities were obtained from the national statistics report and published literature. The model predicted that drug treatment generated quality-adjusted life-years of 13.52 and associated with expected costs of $6825 in comparison with 13.81 and $7328 produced by nondrug treatment over a lifetime horizon among stage I hypertensive patients aged ≥65 years without cardiovascular disease. At a willingness-to-pay threshold of $8836/quality-adjusted life-year (the GDP per capita in 2017), drug treatment only had a 1.8% probability of being cost-effective compared with nondrug treatment after 10 000 probabilistic simulations. Sensitivity analysis of treatment costs, benefits expected from treatment, health utilities, and discount rates did not change the results. Our results suggested that drug treatment was not cost-effective compared with nondrug treatment for stage I hypertensive patients aged ≥65 years without cardiovascular disease in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.